Mode
Text Size
Log in / Sign up
N/A N=154

GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry

Aortic Aneurysm, Thoracic · Descending Thoracic Aortic Dissection · Aortic Diseases · Aorta Thoracic; Traumatic Rupture · Penetrating Ulcer

Enrolled (actual)
154
Serious AEs
51.3%
Results posted
Apr 2024
Primary outcome: Primary: Number of Subjects With All-cause Mortality (Long-term) — 31 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
GORE® TAG® Thoracic Endoprostheses (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
W.L.Gore & Associates
Primary completion
Dec 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Subjects With All-cause Mortality (Long-term)
31
SECONDARY
Number of Subjects With Excluded Aneurysm, Penetrating Aortic Ulcer (PAU), False Lumen or Site of Rupture
50
SECONDARY
Number of Subjects With Neurological Complications
13
SECONDARY
Number of Subjects With Cardiac, Renal, and Pulmonary Complications
32
SECONDARY
Number of Subjects With Device-related Complications
8
SECONDARY
Number of Subjects With Surgical Conversion
SECONDARY
Number of Subjects With Secondary Procedures
27
SECONDARY
Number of Subjects With Disease Related Mortality
5

Summary

This is a French Registry mandated by the French National Health Authority assessing long-term (5-years) safety of the GORE® TAG® Thoracic Endoprosthesis treating diseases of the thoracic aorta.

Eligibility Criteria

Inclusion Criteria

  • Patient where a GORE® TAG® or Conformable GORE® TAG® Thoracic Endoprosthesis is implanted (successfully or not) for the treatment of disease of the descending thoracic aorta.
  • Patient who had previously consented to the collection and processing of personal medical data.
  • Patient older than 18 years at the time of treatment.

Exclusion Criteria

  • Patients who have already received treatment with a thoracic endoprosthesis other than the GORE® TAG® or Conformable GORE® TAG® Thoracic Endoprosthesis and for whom 'revision' or reintervention is required.
  • Patients whose clinical follow-up is not possible (i.e. patients who cannot return for control visits because they live abroad).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02266342). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search